Previous 10 | Next 10 |
home / stock / mrk / mrk articles
Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from hase 3 KEYNOTE-522 trial of Keytruda in high-risk early-stage ...
Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers struggling to fund late-stage...
In today's fast-paced and competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze compani...
Merck (NYSE: MRK) announced that it is discontinuing a cohort of the phase III study evaluating a co-formulation of its blockbuster PD-L1 inhibitor...
Monday, Merck & Co Inc (NYSE:MRK) announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the&n...
Friday, Aethlon Medical Inc (NASDAQ:AEMD) released results from an in vitro binding study of its Hemopurifier in removing extracellular&n...
The first-quarter results of the healthcare sector have been unimpressive, with earnings of 78% of the sector participants that have reported so fa...
Jim Cramer, the host of CNBC’s “Mad Money,” has warned investors about the current state of the economy and suggested strategies ...
ImmunityBio Inc (NASDAQ:IBRX) shares are trading down after an early morning high on Friday after the company announced an exclusive global arrang...
News, Short Squeeze, Breakout and More Instantly...
How one employee's upbringing and career journey have motivated her to fight inequities around the world NORTHAMPTON, MA / ACCESSWIRE / July 16, 2024 / For Priya Agrawal, health equity has been a lifelong concern and a guiding principle in the work she's done across industries. As a young...
Symposia will highlight work to overcome HIV-related stigma and discuss the evolving state of HIV treatment and prevention Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced upcoming data presentations and programming at the 25 th International ...
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret™, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration, as well as preclinical candidates Merck (NYSE: MRK), known as MSD outside of t...